Puma Biotechnology Price To Earning vs. Number Of Shares Shorted
| PBYI Stock | USD 6.22 0.17 2.81% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.86 | 0.7453 |
|
|
Profitability analysis for Puma Biotechnology uses margins and return ratios to relate income to revenue, assets, operating costs, and equity.
Puma Biotechnology's Revenue Breakdown by Segment
Your Equity Center.
Puma Biotechnology Revenue Breakdown by Earning Segment Overview
Earnings estimates provide context for forward-looking performance discussion. They are presented as informational inputs alongside other fundamentals and timeframes.
Quarterly Earnings Growth -0.34 | Earnings Share 0.61 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than book value, which reflects Puma accounting equity. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Market price can move with sentiment, cycles, and liquidity conditions, so it may drift away from fundamentals. Valuation methods compare these perspectives to frame context.
Note that Puma Biotechnology's intrinsic value and market price are different measures derived from different inputs. Analysis often considers earnings, revenue quality, fundamentals, technical signals, competition, and analyst coverage. By contrast, market price reflects the level where buyers and sellers transact.
Puma Biotechnology Number Of Shares Shorted vs. Price To Earning Fundamental Analysis
Sector-based pricing multiples position Puma Biotechnology within its competitive valuation range. Puma Biotechnology holds the number one position in price to earning category among its top compatitors. It holds the number one position in number of shares shorted category among its top compatitors making about 197,777 of Number Of Shares Shorted per Price To Earning. Valuation multiples such as P/E, P/B, and P/S compare Puma Biotechnology to peer earnings performance.Puma Number Of Shares Shorted vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Puma Biotechnology |
| = | 18.52 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Puma Biotechnology |
| = | 3.66 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Puma Number Of Shares Shorted Comparison
Puma Biotechnology is currently under evaluation. in number of shares shorted category among its top compatitors.
Puma Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Puma Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Puma Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Puma Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Puma Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 36 K | 37.8 K | |
| Operating Income | 37.3 M | 39.2 M | |
| Income Before Tax | 35.8 M | 37.6 M | |
| Net Income | 31.1 M | 32.7 M | |
| Net Income From Continuing Ops | 34.8 M | 36.6 M | |
| Non Operating Income Net Other | -10.5 M | -10 M | |
| Total Other Income Expense Net | -1.5 M | -1.6 M | |
| Net Income Applicable To Common Shares | 2.3 K | 2.4 K | |
| Income Tax Expense | 4.7 M | 4.9 M | |
| Net Interest Income | -7 M | -7.3 M | |
| Interest Income | 5.4 M | 5.7 M | |
| Change To Netincome | 21.7 M | 20.6 M | |
| Net Income Per Share | 0.62 | 0.65 | |
| Income Quality | 1.34 | 1.41 | |
| Net Income Per E B T | 0.87 | 0.70 |
Puma Profitability Driver Comparison
Profitability drivers are factors that directly affect the investment outlook for Puma Biotechnology. Investors recognize that outcomes may not unfold as predicted, because unforeseen events and market disruptions can arise at any point and significantly alter the earnings trajectory.
Puma Biotechnology Earnings Estimation Breakdown
The calculation of Puma Biotechnology's earnings per share is based on data from the past 12 consecutive months used for reporting the company's financial figures. The next projected EPS of Puma Biotechnology is estimated to be 0.07 with the future projection ranging from a low of 0.07 to a high of 0.07. Please be aware that this consensus of annual earnings estimates for Puma Biotechnology is based on EPS before non-recurring items.Last Reported EPS
0.07 Lowest | Expected EPS | 0.07 Highest |
Puma Biotechnology Earnings Projection Consensus
A consensus EPS-based estimate above Puma Biotechnology's current price may suggest the market is pricing in excessive pessimism or overlooking near-term catalysts. Conversely, an estimate below market price could reflect a premium valuation that requires sustained earnings growth to justify. Both interpretations demand risk assessment and should not be acted upon in isolation.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 1 | 45.4% | 0.0 | 0.07 | 0.61 |
Puma Biotechnology Earnings per Share Projection vs Actual
When Puma Biotechnology reports actual EPS, investors compare it against the analyst consensus estimate for Puma Biotechnology to judge performance. A beat versus consensus is typically interpreted as positive execution; a miss signals a shortfall relative to expectations. EPS is expressed on a weighted average per-share basis to account for equity changes within the reporting period.Puma Biotechnology Estimated Months Earnings per Share
EPS serves income investors in Puma Biotechnology as a quick gauge of dividend affordability: the higher the EPS relative to the dividend per share, the more cushion management has. However, accounting EPS can diverge from cash-based earnings, so investors should validate EPS signals with operating cash flow and capex data. Comparing Puma Biotechnology's EPS to sector peers provides further context for dividend sustainability.Puma Quarterly Analyst Estimates and Surprise Metrics
Earnings surprise history for Puma Biotechnology's reveals whether the company tends to guide conservatively or struggles to meet analyst expectations. A pattern of consistent beats signals strong management execution; repeated misses may indicate structural challenges. Analyst EPS estimates are formed from a combination of forward guidance, sector trends, and macroeconomic inputs.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-26 | 2025-12-31 | 0.27 | 0.29 | 0.02 | 7 | ||
2025-11-06 | 2025-09-30 | 0.16 | 0.21 | 0.05 | 31 | ||
2025-08-07 | 2025-06-30 | 0.09 | 0.12 | 0.03 | 33 | ||
2025-04-30 | 2025-03-31 | -0.22 | 0.1 | 0.32 | 145 | ||
2025-02-26 | 2024-12-31 | 0.14 | 0.43 | 0.29 | 207 | ||
2024-11-07 | 2024-09-30 | 0.35 | 0.41 | 0.06 | 17 | ||
2024-08-01 | 2024-06-30 | -0.13 | -0.09 | 0.04 | 30 | ||
2024-05-02 | 2024-03-31 | -0.22 | -0.1 | 0.12 | 54 | ||
2024-02-29 | 2023-12-31 | 0.3 | 0.26 | -0.04 | 13 | ||
2023-11-02 | 2023-09-30 | 0.08 | 0.12 | 0.04 | 50 | ||
2023-08-03 | 2023-06-30 | 0.01 | 0.05 | 0.04 | 400 | ||
2023-05-04 | 2023-03-31 | -0.07 | 0.03 | 0.1 | 142 | ||
2023-03-02 | 2022-12-31 | 0.01 | -0.12 | -0.13 | 1300 | ||
2022-11-03 | 2022-09-30 | -0.05 | -0.01 | 0.04 | 80 | ||
2022-08-04 | 2022-06-30 | 0.0102 | 0.21 | 0.1998 | 1958 | ||
2022-05-05 | 2022-03-31 | -0.17 | -0.08 | 0.09 | 52 | ||
2022-03-03 | 2021-12-31 | -0.09 | 0.1 | 0.19 | 211 | ||
2021-11-04 | 2021-09-30 | -0.31 | -0.9 | -0.59 | 190 | ||
2021-08-05 | 2021-06-30 | -0.27 | -0.13 | 0.14 | 51 | ||
2021-05-06 | 2021-03-31 | 0.09 | 0.4 | 0.31 | 344 | ||
2021-02-25 | 2020-12-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2020-11-05 | 2020-09-30 | -0.39 | -0.79 | -0.4 | 102 | ||
2020-08-06 | 2020-06-30 | -0.3 | 0.08 | 0.38 | 126 | ||
2020-05-07 | 2020-03-31 | -0.77 | -0.43 | 0.34 | 44 | ||
2020-02-20 | 2019-12-31 | -0.48 | -0.29 | 0.19 | 39 | ||
2019-11-06 | 2019-09-30 | -0.71 | -0.44 | 0.27 | 38 | ||
2019-08-08 | 2019-06-30 | -0.95 | -0.97 | -0.02 | 2 | ||
2019-05-09 | 2019-03-31 | -0.68 | -0.26 | 0.42 | 61 | ||
2019-02-28 | 2018-12-31 | -0.77 | -0.8 | -0.03 | 3 | ||
2018-11-01 | 2018-09-30 | -0.97 | -0.37 | 0.6 | 61 | ||
2018-08-09 | 2018-06-30 | -1.26 | -1.17 | 0.09 | 7 | ||
2018-05-09 | 2018-03-31 | -1 | -0.65 | 0.35 | 35 | ||
2018-03-01 | 2017-12-31 | -1.97 | -1.71 | 0.26 | 13 | ||
2017-11-09 | 2017-09-30 | -2.58 | -2.07 | 0.51 | 19 | ||
2017-08-09 | 2017-06-30 | -2.04 | -2.1 | -0.06 | 2 | ||
2017-05-10 | 2017-03-31 | -1.98 | -1.97 | 0.01 | 0 | ||
2017-03-01 | 2016-12-31 | -1.92 | -2.04 | -0.12 | 6 | ||
2016-11-09 | 2016-09-30 | -1.96 | -2.02 | -0.06 | 3 | ||
2016-08-09 | 2016-06-30 | -2.18 | -2.05 | 0.13 | 5 | ||
2016-05-10 | 2016-03-31 | -1.99 | -2.19 | -0.2 | 10 | ||
2016-02-29 | 2015-12-31 | -1.95 | -1.9 | 0.05 | 2 | ||
2015-11-09 | 2015-09-30 | -1.84 | -1.87 | -0.03 | 1 | ||
2015-08-10 | 2015-06-30 | -1.55 | -2.01 | -0.46 | 29 | ||
2015-05-11 | 2015-03-31 | -1.35 | -1.66 | -0.31 | 22 | ||
2015-03-02 | 2014-12-31 | -1.19 | -1.57 | -0.38 | 31 | ||
2014-11-10 | 2014-09-30 | -1.21 | -1.19 | 0.02 | 1 | ||
2014-08-11 | 2014-06-30 | -0.66 | -1.29 | -0.63 | 95 | ||
2014-05-12 | 2014-03-31 | -0.48 | -0.67 | -0.19 | 39 | ||
2014-03-03 | 2013-12-31 | -0.49 | -0.56 | -0.07 | 14 | ||
2013-11-12 | 2013-09-30 | -0.46 | -0.5 | -0.04 | 8 | ||
2013-08-06 | 2013-06-30 | -0.43 | -0.44 | -0.01 | 2 | ||
2013-05-09 | 2013-03-31 | -0.63 | -0.41 | 0.22 | 34 | ||
2013-03-31 | 2012-12-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2012-11-14 | 2012-09-30 | -0.52 | -1.29 | -0.77 | 148 | ||
2012-08-14 | 2012-06-30 | -0.35 | -0.22 | 0.13 | 37 | ||
2012-05-15 | 2012-03-31 | -0.25 | -0.57 | -0.32 | 128 |
Use Puma Biotechnology in pair-trading
Pair trading with Puma Biotechnology can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Puma Biotechnology Pair Trading
Puma Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to Puma Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Puma Biotechnology when you sell it.
The correlation of Puma Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1.
Correlation analysis and pair trading evaluation for Puma Biotechnology can be used to frame hedging context. The approach can be applied within sectors or across broader universes.Use Investing Themes to Complement your Puma Biotechnology position
Using Puma Biotechnology inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Utilities ETFs Thematic Idea Now
Utilities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
More Resources for Puma Stock Analysis
A structured review of Puma Biotechnology often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Puma Biotechnology Stock. Outlined below are key reports that provide context for Puma Biotechnology Stock:Your Equity Center. For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Analysis related to Puma Biotechnology should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Projecting Puma Biotechnology's profitability starts with historical financial statements. Core documents include the income statement, balance sheet, and cash-flow statement.